Pfizer Moves Over Half a Billion for Wilson Disease Treatment
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
Pfizer Inc. (NYSE: PFE | PFE Price Prediction) has announced that it has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer is looking to collaborate with Vivet on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease.
Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. This disease may result in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can be fatal, that can only be cured by liver transplantation. Existing therapies for Wilson disease have sub-optimal efficacy or significant side effects for many patients.
Under the terms of the transaction, Pfizer paid approximately €45 million ($51 million) upon signing and may pay up to €560 million ($635.8 million) inclusive of the option exercise payment and subject to certain clinical, regulatory, and commercial milestones.
At any point, Pfizer can exercise its option to acquire 100% of Vivet following the company’s delivery of certain data from the Phase 1/2 clinical trial for VTX-801.
[nativounit]
Mikael Dolsten, Pfizer’s chief scientific officer and president or Worldwide Research, Development and Medical, commented:
Pfizer strives to provide meaningful enhancements to the lives of patients with rare diseases. Our partnership with Vivet offers an important expansion of Pfizer’s commitment to collaborate with the scientific community and to accelerate our leading AAV-directed gene therapy portfolio.
Shares of Pfizer were last seen down about 1% at $41.94 on Wednesday, in a 52-week range of $34.32 to $46.47. The consensus price target is $44.14.
[recirclink id=535587]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
